# A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers

> **NCT06008015** · PHASE1 · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 44 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** BR1015
- **DRUG:** BR1015-1
- **DRUG:** BR1015-2

## Key facts

- **NCT ID:** NCT06008015
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-04
- **Primary completion:** 2023-10-03
- **Final completion:** 2023-10-03
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2023-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06008015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06008015, "A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT06008015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*